Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 15;15(24):5853.
doi: 10.3390/cancers15245853.

The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review

Affiliations
Review

The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review

Emily Flom et al. Cancers (Basel). .

Abstract

The modern rectal cancer treatment paradigm offers additional opportunities for organ preservation, most notably via total neoadjuvant therapy (TNT) and consideration for a watch-and-wait (WW) surveillance-only approach. A major barrier to widespread implementation of a WW approach to rectal cancer is the potential discordance between a clinical complete response (cCR) and a pathologic complete response (pCR). In the pre-TNT era, the identification of predictors of pCR after neoadjuvant therapy had been previously studied. However, the last meta-analysis to assess the summative evidence on this important treatment decision point predates the acceptance and dissemination of TNT strategies. The purpose of this systematic review was to assess preoperative predictors of pCR after TNT to guide the ideal selection criteria for WW in the current era. An exhaustive literature review was performed and the electronic databases Embase, Ovid, MEDLINE, PubMed, and Cochrane were comprehensively searched up to 27 June 2023. Search terms and their combinations included "rectal neoplasms", "total neoadjuvant therapy", and "pathologic complete response". Only studies in English were included. Randomized clinical trials or prospective/retrospective cohort studies of patients with clinical stage 2 or 3 rectal adenocarcinoma who underwent at least 8 weeks of neoadjuvant chemotherapy in addition to chemoradiotherapy with pCR as a measured study outcome were included. In this systematic review, nine studies were reviewed for characteristics positively or negatively associated with pCR or tumor response after TNT. The results were qualitatively grouped into four categories: (1) biochemical factors; (2) clinical factors; (3) patient demographics; and (4) treatment sequence for TNT. The heterogeneity of studies precluded meta-analysis. The level of evidence was low to very low. There is minimal data to support any clinicopathologic factors that either have a negative or positive relationship to pCR and tumor response after TNT. Additional data from long-term trials using TNT is critical to better inform those considering WW approaches following a cCR.

Keywords: neoadjuvant therapy; pathologic complete response; rectal cancer; watch-and-wait.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of systematic review.

References

    1. Liu S., Jiang T., Xiao L., Yang S., Liu Q., Gao Y., Chen G., Xiao W. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021;26:e1555–e1566. doi: 10.1002/onco.13824. - DOI - PMC - PubMed
    1. Cercek A., Goodman K.A., Hajj C., Weisberger E., Segal N.H., Reidy-Lagunes D.L., Stadler Z.K., Wu A.J., Weiser M.R., Paty P.B., et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J. Natl. Compr. Cancer Netw. 2014;12:513–519. doi: 10.6004/jnccn.2014.0056. - DOI - PMC - PubMed
    1. Cercek A., Roxburgh C.S.D., Strombom P., Smith J.J., Temple L.K.F., Nash G.M., Guillem J.G., Paty P.B., Yaeger R., Stadler Z.K., et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 2018;4:e180071. doi: 10.1001/jamaoncol.2018.0071. - DOI - PMC - PubMed
    1. Chau I., Brown G., Cunningham D., Tait D., Wotherspoon A., Norman A.R., Tebbutt N., Hill M., Ross P.J., Massey A., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J. Clin. Oncol. 2006;24:668–674. doi: 10.1200/JCO.2005.04.4875. - DOI - PubMed
    1. Rettig R.L., Beard B.W., Ryoo J.J., Kulkarni S., Gulati M., Tam M., Attaluri V. Total Neoadjuvant Therapy Significantly Increases Complete Clinical Response. Dis. Colon Rectum. 2023;66:374–382. doi: 10.1097/DCR.0000000000002290. - DOI - PubMed

LinkOut - more resources